Tag Archives: ARWR

Investors Buy Large Volume of Arrowhead Pharmaceuticals Put Options (ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw unusually large options trading activity on Tuesday. Investors acquired 2,660 put options on the stock. This is an increase of 2,318% compared to the average daily volume of 110 put options.

In other news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 27th. The shares were sold at an average price of $8.00, for a total value of $160,000.00. Following the transaction, the chief financial officer now directly owns 330,815 shares in the company, valued at approximately $2,646,520. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Richard Anzalone sold 300,000 shares of the firm’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $7.43, for a total transaction of $2,229,000.00. Following the completion of the transaction, the chief executive officer now owns 2,194,789 shares in the company, valued at $16,307,282.27. The disclosure for this sale can be found here. Over the last three months, insiders have sold 465,000 shares of company stock valued at $3,432,350. 4.60% of the stock is owned by company insiders.

Get Arrowhead Pharmaceuticals alerts:

Large investors have recently modified their holdings of the stock. Quantitative Systematic Strategies LLC bought a new stake in Arrowhead Pharmaceuticals in the 1st quarter valued at about $100,000. Vanguard Capital Wealth Advisors bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $119,000. Macquarie Group Ltd. bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $123,000. Jane Street Group LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $130,000. Finally, Trexquant Investment LP bought a new stake in Arrowhead Pharmaceuticals in the 1st quarter valued at about $139,000. Hedge funds and other institutional investors own 28.50% of the company’s stock.

A number of research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. B. Riley raised their price target on shares of Arrowhead Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Monday, February 12th. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, February 19th. Finally, Piper Jaffray raised their price target on shares of Arrowhead Pharmaceuticals to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 8th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Arrowhead Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $9.00.

Shares of NASDAQ:ARWR opened at $9.60 on Wednesday. Arrowhead Pharmaceuticals has a fifty-two week low of $9.21 and a fifty-two week high of $9.74. The company has a current ratio of 10.16, a quick ratio of 10.16 and a debt-to-equity ratio of 0.02.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.65 million for the quarter, compared to the consensus estimate of $4.04 million. Arrowhead Pharmaceuticals had a negative net margin of 199.55% and a negative return on equity of 50.05%. research analysts anticipate that Arrowhead Pharmaceuticals will post -0.73 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

3 Biotech Stocks That Soared This Week: Are They Buys?

Sell in May and go away? That old adage would have been horrible advice for investors who owned three biotech stocks that soared over the last week.

ARMO BioSciences (NASDAQ:ARMO), Opko Health (NASDAQ:OPK), and Arrowhead Pharmaceuticals (NASDAQ:ARWR) chalked up huge gains over the last five days. What sent these biotech stocks into orbit? And are they still smart picks for investors? Here’s what you need to know about the fantastic week for ARMO, Opko, and Arrowhead along with what could be next for each stock.

Five test tubes with increasing levels of green liquid from left to right and green arrow drawn behind them curving upward

Image source: Getty Images.

1. ARMO BioSciences: We hardly knew ye

ARMO BioSciences stock skyrocketed 78% this week. The biotech announced on Thursday that it was being acquired by Eli Lilly (NYSE:LLY) for $1.6 billion. What’s especially notable about this acquisition is that ARMO conducted its initial public offering (IPO) less than four months ago.

What made ARMO so attractive to Lilly? The small biotech’s lead product candidate, AM0010, also known as pegilodecakin. AM0010a long-acting form of recombinant humanInterleukin 10(IL-10) that stimulates white blood cells calledCD8+T cells. These T cells recognize and kill cancer cells. The drug is currently being evaluated in a phase 3 study for treatingpancreatic cancer and in earlier-stage studies targeting other types of cancer.

Lilly saw AM0010 as a great addition to its current oncology lineup, which includes Cyramza, Verzenio, and three pipeline candidates in phase 2 clinical studies. The acquisition is expected to close by the end of the second quarter.

2. Opko Health: A Rayaldee of sunshine

Opko Health didn’t see its stock pop as much as ARMO BioSciences, but the biotech did enjoy a big gain of 42% this week. The catalyst for Opko was the company’s better-than-expected first-quarter results announced on Tuesday.

Wall Street analysts expected Opko to report Q1 revenue of nearly $237 million. The company reported revenue of close to $255 million. But while that figure beat what analysts projected, it came in right in line with what Opko’s expectations.

The best news from Opko’s quarterly update for investors was thatchronic kidney disease drug Rayaldee appears to be picking up momentum. Opko stated that Q1 total prescriptions for the drug jumped 731% year over year and were 38% higher than the fourth quarter of 2017. The company also expects that itslaboratory diagnostic business, Bio-Reference Laboratories, will see improvement this year.

3. Arrowhead Pharmaceuticals: Giving more of the silent treatment

Arrowhead Pharmaceuticals stock jumped 38% this week. Although the company announced its Q1 financial results on Tuesday, the bigger story for Arrowhead wasn’t about the top and bottom lines. Instead, investors were encouraged by the biotech’s pipeline updates.

“Target the gene, silence the disease” is Arrowhead’s slogan. The company uses RNA interference (RNAi) to silence gene expression and regulate the production of proteins. This approach allows focused targeting of a wide range of genes and disease pathways that have been difficult to address in the past.

Arrowhead announced this week that it had initiated dosing in two phase 1 clinical studies evaluating RNAi therapies in treating rare genetic diseasealpha-1 antitrypsin de铿ciency and hepatitis B. The company also reported that it plans to submit for European approval to begin clinical studies for two preclinical candidates, ARO-APOC3 and ARO-ANG3, later this year.

Are they buys?

Congratulations to those who already bought ARMO BioSciences stock. For everyone else, though, it’s too late to profit from the biotech.But what about Opko Health and Arrowhead?

It’s great to see Rayaldee begin to gain some traction. Opko also is seeing some growth for its4Kscore blood test for detecting prostate cancer. And new leadership at Bio-Reference Labs could get that ship headed in the right direction. My view on Opko is that it could be a winner over the long run, but for now, I’d rather wait to see additional improvement.

I’m intrigued by Arrowhead, though. Alnylam Pharmaceuticals has already shown that RNA interference can be effective and expects to soon win Food and Drug Administration approval for patisiran in treatinghereditary ATTR amyloidosis. Arrowhead could also be on the right track with its RNAi programs.

The main drawback to Arrowhead is that its pipeline candidates still have a long way to go. Arrowhead is the kind of stock that could make a ton of money — or lose a ton of money — for shareholders. My hunch is that it will be a winner over the long run, but I’m not ready to step out on a limb and call the stock a buy. There’s simply too much risk right now despite a lot of potential for this clinical-stage biotech.

A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Pre-open movers

U.S. stock futures traded higher in early pre-market trade, ahead of earnings from several companies. The Producer Price Index for April will be released at 8:30 a.m. ET, while data on wholesale trade inventories for March will be released at 10:00 a.m. ET. Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 1:15 p.m. ET.

Futures for the Dow Jones Industrial Average rose 125 points to 24,432.00, while the Standard & Poor’s 500 index futures rose 11.50 points to 2,681.75. Futures for the Nasdaq 100 index climbed 22 points to 6,841.00.

Oil prices traded higher as Brent crude futures rose 2.42 percent to trade at $76.66 per barrel, while US WTI crude futures rose 2.49 percent to trade at $70.78 a barrel. The Energy Information Administration’s weekly report on petroleum inventories in the U.S. is schedule for release at 10:30 a.m. ET.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index rising 0.07 percent, STOXX Europe 600 Index gaining 0.17 percent and German DAX 30 index gaining 0.05 percent. The UK's FTSE index was trading higher by 0.39 percent, while French CAC 40 Index fell 0.06 percent.

In Asian markets, Japan’s Nikkei Stock Average fell 0.44 percent, Hong Kong’s Hang Seng Index rose 0.44 percent, China’s Shanghai Composite Index slipped 0.07 percent and India’s BSE Sensex rose 0.29 percent.

Broker Recommendation

Analysts at Cantor Fitzgerald upgraded Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) from Neutral to Overweight.

Arrowhead Pharmaceuticals shares fell 0.26 percent to close at $7.75 on Tuesday.

Breaking news

Delphi Technologies PLC (NYSE: DLPH) reported upbeat earnings for its first quarter.
Office Depot Inc (NASDAQ: ODP) reported in-line earnings for its first quarter, while sales exceeded estimates. The company also raised its FY18 guidance.
Walmart Inc (NYSE: WMT) announced plans to invest $16 billion in Flipkart for initial stake of 77 percent.
Tripadvisor Inc (NASDAQ: TRIP) reported stronger-than-expected results for its first quarter on Tuesday.